Phase 2 study researchers were unable to show that duloxetine is more beneficial than placebo in preventing chemotherapy-induced peripheral neuropathy, but the findings may have been confounded by a high placebo response rate (Abstract 12010).
Clinical trials are increasingly staff intensive and complex to recruit for and manage, creating infrastructure barriers for community-based and rural cancer clinics. Large language models…
Increasing evidence demonstrates that approximately one-half of patients with high-risk or locally advanced cutaneous squamous cell carcinoma achieve a pathologic complete response following 2 to…
ASCO and the Network for Collaborative Oncology Development & Advancement have issued updated standards for dispensing oral anticancer medications and supportive care medications through a…
Ruth Porat, President and Chief Investment Officer of Alphabet Inc. and its subsidiary, Google, will highlight the potential of artificial intelligence and machine learning to…
Incidental CT findings, particularly on lung cancer screening (LCS), characterize interstitial lung abnormalities in Asian populations.
Meet the 2025–2026 ASCO Leadership Development Program and Education Scholars Participants / ASCO, ASCO 2025, ASCO Education Scholars, ASCO Leadership
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations…
Results from the phase 2 PROSPECT trial show that once-daily tirabrutinib could be a potentially effective treatment for patients with relapsed/refractory primary central nervous system…
